US2016279356A1PendingUtilityA1

Inhaler for the administration of an anticholinergic

67
Assignee: BOEHRINGER INGELHEIM PHARMAPriority: Apr 9, 2002Filed: Jun 8, 2016Published: Sep 29, 2016
Est. expiryApr 9, 2022(expired)· nominal 20-yr term from priority
Inventors:Bernd Zierenberg
A61K 9/0075A61M 15/0041A61M 15/0075A61M 15/0086A61M 2205/75A61K 31/439A61M 2202/064A61K 9/145A61M 15/0045A61M 15/0026A61M 15/0091A61M 15/0021A61M 15/0028A61M 15/0051A61K 31/46
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An inhaler for administration of powdered preparations containing tiotropium, wherein the inhaler displays a flow resistance of 0.01-0.1 √{square root over (kPa)} min/L and comprises a housing, a deck with air inlet ports and a screen secured by a screen housing, an inhalation chamber connected to the deck on which there is a push button provided with two sharpened pins and movable counter to a spring, a mouthpiece which is connected to the housing, the deck and a cover via a spindle to enable the cover to be flipped open or shut, and three holes with diameters below 1 mm in a central region of the deck around a capsule chamber and underneath the screen housing and screen.

Claims

exact text as granted — not AI-modified
1 . An inhaler for an inhalable powder, wherein the inhaler comprises: a housing, a deck in which there are air inlet ports and which is provided with a screen secured by a screen housing, an inhalation chamber connected to the deck on which there is a push button provided with two sharpened pins and movable counter to a spring, a mouthpiece which is connected to the housing, the deck, and a cover via a hinge spindle to enable it to be flipped open or shut, and three holes with diameters below 1 mm in the central region around the capsule chamber and underneath the screen housing and screen, wherein the inhaler has a reduced width in the range between the deck and the housing near to the hinge spindle, which forms the entrance slit for the air, and the inhaler displays a flow resistance of about 0.01 to 0.1 √{square root over (kPa)} min/L. 
     
     
         2 . The inhaler according to  claim 1 , wherein the inhalable powder contains tiotropium is in an amount of 0.001% to 5%, in admixture with a physiologically acceptable excipient with an average particle size of between 10 μm to 500 μm. 
     
     
         3 . The inhaler according to  claim 1 , wherein the inhaler has a flow resistance of about 0.02 to 0.06 √{square root over (kPa)} min/L. 
     
     
         4 . The inhaler according to  claim 2 , wherein the inhaler has a flow resistance of about 0.02 to 0.06 √{square root over (kPa)} min/L. 
     
     
         5 . The inhaler according to  claim 1 , wherein the tiotropium is a chloride, bromide, iodide, methanesulfonate, p-toluenesulfonate, or methylsulfate salt. 
     
     
         6 . The inhaler according to  claim 2 , wherein the tiotropium is a chloride, bromide, iodide, methanesulfonate, p-toluenesulfonate, or methylsulfate salt. 
     
     
         7 . The inhaler according to  claim 3 , wherein the tiotropium is a chloride, bromide, iodide, methanesulfonate, p-toluenesulfonate, or methylsulfate salt. 
     
     
         8 . The inhaler according to  claim 4 , wherein the tiotropium is a chloride, bromide, iodide, methanesulfonate, p-toluenesulfonate, or methylsulfate salt. 
     
     
         9 . The method according to  claim 5 , wherein the tiotropium is crystalline tiotropium bromide monohydrate. 
     
     
         10 . The method according to  claim 6 , wherein the tiotropium is crystalline tiotropium bromide monohydrate. 
     
     
         11 . The method according to  claim 7 , wherein the tiotropium is crystalline tiotropium bromide monohydrate. 
     
     
         12 . The method according to  claim 8 , wherein the tiotropium is crystalline tiotropium bromide monohydrate. 
     
     
         13 . An inhalation kit comprising:
 (a) an inhaler according to  claim 1 ; and   (b) an inhalable powder containing tiotropium.   
     
     
         14 . The inhalation kit according to  claim 13 , wherein the inhalable powder containing tiotropium is in an amount of 0.001% to 5%, in admixture with a physiologically acceptable excipient with an average particle size of between 10 μm to 500 μm. 
     
     
         15 . The inhalation kit according to  claim 13 , wherein the inhaler has a flow resistance of about 0.02 to 0.06 √{square root over (kPa)} min/L. 
     
     
         16 . The inhalation kit according to  claim 14 , wherein the inhaler has a flow resistance of about 0.02 to 0.06 √{square root over (kPa)} min/L. 
     
     
         17 . The inhalation kit according to  claim 13 , wherein the tiotropium is a chloride, bromide, iodide, methanesulfonate, p-toluenesulfonate, or methylsulfate salt. 
     
     
         18 . The inhalation kit according to  claim 14 , wherein the tiotropium is a chloride, bromide, iodide, methanesulfonate, p-toluenesulfonate, or methylsulfate salt. 
     
     
         19 . The inhalation kit according to  claim 15 , wherein the tiotropium is a chloride, bromide, iodide, methanesulfonate, p-toluenesulfonate, or methylsulfate salt. 
     
     
         20 . The inhalation kit according to  claim 16 , wherein the tiotropium is a chloride, bromide, iodide, methanesulfonate, p-toluenesulfonate, or methylsulfate salt. 
     
     
         21 . The inhalation kit according to  claim 17 , wherein the tiotropium is crystalline tiotropium bromide monohydrate. 
     
     
         22 . The inhalation kit according to  claim 18 , wherein the tiotropium is crystalline tiotropium bromide monohydrate. 
     
     
         23 . The inhalation kit according to  claim 19 , wherein the tiotropium is crystalline tiotropium bromide monohydrate. 
     
     
         24 . The inhalation kit according to  claim 20 , wherein the tiotropium is crystalline tiotropium bromide monohydrate. 
     
     
         25 . A method for the administration of an inhalable powder containing tiotropium, the method comprising using an inhaler according to  claim 1 . 
     
     
         26 . A method for the administration of an inhalable powder containing tiotropium, the method comprising using an inhalation kit according to  claim 13 .

Join the waitlist — get patent alerts

Track US2016279356A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.